PHARMACOTHERAPY AND EVIDENCE BASED MEDICINE: Edited by Enrico Compalati and Derek Chuβ-Blockers and angiotensin-converting enzyme inhibitors with sublingual immunotherapy: are risks related to individual product safety profile?Smith, Derek M.a; Coop, Christopher A.a; Freeman, Theodore M.bAuthor Information aDepartment of Allergy and Immunology, Wilford Hall Ambulatory Surgical Center bSan Antonio Asthma and Allergy Clinic, San Antonio, Texas, USA Correspondence to Derek M. Smith, MD, Department of Allergy and Immunology, Wilford Hall Ambulatory Surgical Center, 1100 Wilford Hall Loop, Lackland AFB, San Antonio, TX 78236, USA. Tel: +1 210 292 4278; fax: +1 210 292 7033; e-mail: email@example.com Current Opinion in Allergy and Clinical Immunology: August 2020 - Volume 20 - Issue 4 - p 401-406 doi: 10.1097/ACI.0000000000000657 Buy Metrics Abstract Purpose of review The objective of this article is to review the available literature regarding the risks associated with sublingual immunotherapy and angiotensin-converting enzyme (ACE) inhibitors or β-blocker use. It also evaluates for any differences in these risks among the available sublingual immunotherapy (SLIT) tablets. Recent findings A literature search was conducted in PubMed to identify peer-reviewed articles using the following keywords: anaphylaxis, ACE inhibitor, β-blocker, and sublingual immunotherapy. Minimal data exist regarding their safety of SLIT in patients concomitantly taking ACE inhibitors or β-blockers. The adverse reaction rates seem similar between SLIT products. Summary A risk-versus-benefit discussion should be communicated with the patient taking a β-blocker before beginning SLIT but automatic denial of SLIT to these patients is not warranted. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.